Progress of new drugs on relapsed/refractory peripheral T-cell lymphoma / 国际肿瘤学杂志
Ke ZHAO; Huaqing WANG.
Journal of International Oncology
; (12): 321-326, 2020.
Artículo
en Zh
| WPRIM | ID: wpr-863492
Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous diseases originating from post-thymic T-cells, with poor prognosis using traditional therapy, especially in patients with relapsed/refractory PTCLs (r/rPTCLs). In recent years, a variety of new anti-tumor drugs have emerged in the treatment of r/rPTCLs, including different types of enzyme inhibitors, monoclonal antibodies, immunomodulators and immune checkpoint inhibitors, which have been proved to be effective. The discovery and clinical application of new drugs are expected to improve the outcomes of the diseases.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados